MedTrace Logo

Utility of Pharmacogenomic Testing and Postoperative Dental Pain Outcomes

NCT02932579 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2022-03-16

Study results available
· View outcomes & findings →

Summary

Opioid analgesics are the most common postoperative pain medications used among dentists in the United States.Although these medications are highly effective in the postoperative dental pain management, not all patients optimally benefit from this therapy. Many suffer adverse consequences such as nausea, emesis, and psychomotor impairment, and there is a high prevalence of opioid prescription misuse among substance abusers within the dental patient population.

The use of non-opioid analgesics including ibuprofen and acetaminophen in the management of postoperative dental pain has demonstrated equivalent or superior analgesic effects compared to opioid analgesic therapies, typically with significantly less adverse effects.However, despite these results, dentists have encountered a high variability in the success of non-opioid analgesic responses among the postoperative dental pain population.Thus, new strategies for earlier recognition of analgesic responses for pain medications is fundamental in the field of dentistry. Therefore, this study will evaluate the clinical utility of pharmacogenomic testing in acute postoperative dental pain management among healthy adults who undergo extraction of impacted mandibular third molar.

Conditions

Interventions

OTHER

Pharmacogenomic Testing

Saliva collection (5mL)

DRUG

Ibuprofen

400 mg

DRUG

hydroxycontin/acetominophen

hydroxycontin 2.5 mg, acetominophen 325 mg

DRUG

acetominophen

650 mg

DRUG

Oxycontin/acetominophen

5mg Oxycontin, 325 mg acetominophen. This will be a rescue medication is the other three pain medications do not work.

Sponsors & Collaborators

  • University of Rochester

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-07-01
Primary Completion
2021-01-13
Completion
2021-01-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02932579 on ClinicalTrials.gov